Zhejiang Jingxin Pharmaceutical Co., Ltd.
Simbolis: 002020.SZ
SHZ
12.29
CNYRinkos kaina šiandien
16.3059
P/E santykis
-1.6917
PEG koeficientas
10.58B
MRK kapitalizacija
- 0.02%
DIV pajamingumas
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 7335.53 | 2019.9 | 1915.4 | 1977.2 | |||||||||||||||||||||||
balance-sheet.row.short-term-investments | 1127.56 | 609.3 | 366.9 | 422.4 | |||||||||||||||||||||||
balance-sheet.row.net-receivables | 2431.47 | 664 | 570 | 586.7 | |||||||||||||||||||||||
balance-sheet.row.inventory | 2703.54 | 652.7 | 773.7 | 649.1 | |||||||||||||||||||||||
balance-sheet.row.other-current-assets | 299.73 | 17.1 | 22.1 | 16.5 | |||||||||||||||||||||||
balance-sheet.row.total-current-assets | 12770.27 | 3353.7 | 3281.2 | 3229.5 | |||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 8656.05 | 2309.8 | 1632.1 | 1262.9 | |||||||||||||||||||||||
balance-sheet.row.goodwill | 1393.94 | 348.5 | 348.5 | 257.9 | |||||||||||||||||||||||
balance-sheet.row.intangible-assets | 1617.31 | 401.3 | 418.6 | 137.7 | |||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 3011.25 | 749.7 | 767.1 | 395.6 | |||||||||||||||||||||||
balance-sheet.row.long-term-investments | 2754.28 | 1471.1 | 218.9 | 119.5 | |||||||||||||||||||||||
balance-sheet.row.tax-assets | 297.88 | 81 | 75.1 | 62.5 | |||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 4007.56 | 21.2 | 1388.1 | 1345.3 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 18727.02 | 4632.8 | 4081.4 | 3185.8 | |||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.total-assets | 31497.29 | 7986.6 | 7362.6 | 6415.4 | |||||||||||||||||||||||
balance-sheet.row.account-payables | 3316.2 | 610.8 | 719.1 | 435.1 | |||||||||||||||||||||||
balance-sheet.row.short-term-debt | 1704.65 | 621.3 | 253.3 | 161.9 | |||||||||||||||||||||||
balance-sheet.row.tax-payables | 199.19 | 44.3 | 105.4 | 95 | |||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 139.56 | 31.2 | 43 | 6.6 | |||||||||||||||||||||||
Deferred Revenue Non Current | 1091.72 | 268.8 | 270.6 | 128.7 | |||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 254.92 | - | - | - | |||||||||||||||||||||||
balance-sheet.row.other-current-liab | 805.52 | 789.3 | 761.9 | 4.7 | |||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 1227.33 | 102.8 | 375.2 | 192.6 | |||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 139.56 | 31.2 | 43 | 6.5 | |||||||||||||||||||||||
balance-sheet.row.total-liab | 9357.68 | 2177.6 | 2190.6 | 1577.7 | |||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
balance-sheet.row.common-stock | 3444.12 | 861 | 861 | 905.3 | |||||||||||||||||||||||
balance-sheet.row.retained-earnings | 9981.01 | 2540.1 | 2228.8 | 1871.1 | |||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 4893.06 | 388 | 336.1 | 285.9 | |||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3443.45 | 1723.3 | 1720.2 | 1755.1 | |||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 21761.63 | 5512.4 | 5146.1 | 4817.4 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 31497.29 | 7986.6 | 7362.6 | 6415.4 | |||||||||||||||||||||||
balance-sheet.row.minority-interest | 109.17 | 27.8 | 25.8 | 20.2 | |||||||||||||||||||||||
balance-sheet.row.total-equity | 21870.8 | 5540.2 | 5172 | 4837.7 | |||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 31497.29 | - | - | - | |||||||||||||||||||||||
Total Investments | 3881.85 | 2080.4 | 585.8 | 541.9 | |||||||||||||||||||||||
balance-sheet.row.total-debt | 1844.21 | 652.5 | 296.3 | 168.5 | |||||||||||||||||||||||
balance-sheet.row.net-debt | -4363.76 | -758.2 | -1252.2 | -1386.3 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 638.91 | 618.9 | 667.8 | 614.7 | ||||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 10.99 | 221.5 | 166.9 | 143.6 | ||||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 2.8 | -12.2 | -5.8 | ||||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -488 | 12.2 | 5.8 | ||||||||||||||||||||||
cash-flows.row.change-in-working-capital | 29.56 | -45 | 21.3 | -391.7 | ||||||||||||||||||||||
cash-flows.row.account-receivables | -93.48 | -93.5 | -250.9 | -208.6 | ||||||||||||||||||||||
cash-flows.row.inventory | 123.04 | 123 | -103 | -147.8 | ||||||||||||||||||||||
cash-flows.row.account-payables | 0 | -74.6 | 387.4 | -41.8 | ||||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -12.2 | 6.5 | ||||||||||||||||||||||
cash-flows.row.other-non-cash-items | 275.34 | 514.5 | -0.3 | -1.5 | ||||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 954.8 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -339.78 | -519.5 | -515.6 | -404.4 | ||||||||||||||||||||||
cash-flows.row.acquisitions-net | 9.85 | 10.3 | 5.2 | 8.3 | ||||||||||||||||||||||
cash-flows.row.purchases-of-investments | -870.2 | -1175.2 | -1058 | -861.7 | ||||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1011.18 | 915 | 833.9 | 1407.9 | ||||||||||||||||||||||
cash-flows.row.other-investing-activites | 311.97 | 0 | -3.2 | -5.3 | ||||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -189.34 | -769.4 | -737.7 | 144.7 | ||||||||||||||||||||||
cash-flows.row.debt-repayment | -339.22 | -35 | -150 | -300.3 | ||||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
cash-flows.row.dividends-paid | -258.11 | -258.3 | -258.6 | -232.2 | ||||||||||||||||||||||
cash-flows.row.other-financing-activites | 593.64 | -4 | 220.5 | 653.3 | ||||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -180.91 | -245.6 | -188 | 120.8 | ||||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 5.78 | 2.7 | 14.9 | -3.8 | ||||||||||||||||||||||
cash-flows.row.net-change-in-cash | 684.27 | -77.8 | -55 | 626.8 | ||||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 5962.04 | 1410.6 | 1463.7 | 1512.8 | ||||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 5277.77 | 1488.5 | 1518.7 | 886 | ||||||||||||||||||||||
cash-flows.row.operating-cash-flow | 954.8 | 824.7 | 855.8 | 365 | ||||||||||||||||||||||
cash-flows.row.capital-expenditure | -339.78 | -519.5 | -515.6 | -404.4 | ||||||||||||||||||||||
cash-flows.row.free-cash-flow | 615.02 | 305.2 | 340.2 | -39.4 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 4082.46 | 3952.1 | 3779.8 | 3336 | |||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 2026.66 | 2048.3 | 1766.1 | 1472.8 | |||||||||||||||||||||||
income-statement-row.row.gross-profit | 2055.8 | 1903.8 | 2013.7 | 1863.2 | |||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||
income-statement-row.row.research-development | 410.79 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 78.1 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 790.89 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-expenses | -21.94 | 6.4 | 135.7 | 99.8 | |||||||||||||||||||||||
income-statement-row.row.operating-expenses | 1442.43 | 1324.6 | 1354.4 | 1250.3 | |||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 3469.09 | 3372.9 | 3120.5 | 2723 | |||||||||||||||||||||||
income-statement-row.row.interest-income | 43.91 | 60.3 | 65.6 | 48.1 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 6.56 | 7.3 | 6 | 3.7 | |||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 790.89 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 77.27 | 134.9 | -6.3 | 1.5 | |||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | -21.94 | 6.4 | 135.7 | 99.8 | |||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 77.27 | 134.9 | -6.3 | 1.5 | |||||||||||||||||||||||
income-statement-row.row.interest-expense | 6.56 | 7.3 | 6 | 3.7 | |||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 82.38 | 221.5 | 182.9 | 170.6 | |||||||||||||||||||||||
income-statement-row.row.ebitda-caps | 740.39 | - | - | - | |||||||||||||||||||||||
income-statement-row.row.operating-income | 658.01 | 579.2 | 756.6 | 693 | |||||||||||||||||||||||
income-statement-row.row.income-before-tax | 735.28 | 714.1 | 750.3 | 694.5 | |||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 90.4 | 84.6 | 82.5 | 79.8 | |||||||||||||||||||||||
income-statement-row.row.net-income | 638.91 | 618.9 | 662.3 | 612.5 |
Dažnai užduodami klausimai
Kas yra Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) bendras turtas?
Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) bendras turtas yra 7986556907.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 2117348157.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.504.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.718.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.157.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.161.
Kas yra Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 618898033.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 652489982.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 1324586158.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 2069633166.000.